Bioxytran Stock Performance
| BIXT Stock | USD 0.08 0.01 14.00% |
On a scale of 0 to 100, Bioxytran holds a performance score of 4. The firm shows a Beta (market volatility) of -1.72, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bioxytran are expected to decrease by larger amounts. On the other hand, during market turmoil, Bioxytran is expected to outperform it. Please check Bioxytran's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Bioxytran's price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bioxytran are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, Bioxytran unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Bioxytran |
Bioxytran Relative Risk vs. Return Landscape
If you would invest 6.90 in Bioxytran on October 2, 2025 and sell it today you would earn a total of 0.84 from holding Bioxytran or generate 12.17% return on investment over 90 days. Bioxytran is currently generating 0.4489% in daily expected returns and assumes 7.429% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of otc stocks are less volatile than Bioxytran, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bioxytran Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioxytran's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Bioxytran, and traders can use it to determine the average amount a Bioxytran's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0604
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIXT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Bioxytran is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bioxytran by adding it to a well-diversified portfolio.
Bioxytran Fundamentals Growth
Bioxytran OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Bioxytran, and Bioxytran fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioxytran OTC Stock performance.
| Return On Asset | -7.04 | |||
| Current Valuation | 19.06 M | |||
| Shares Outstanding | 144.64 M | |||
| Price To Sales | 532.56 X | |||
| EBITDA | (3.59 M) | |||
| Cash And Equivalents | 500.68 K | |||
| Total Debt | 2.17 M | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (839.44 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 370.94 K | |||
| Retained Earnings | (11.22 M) | |||
About Bioxytran Performance
Assessing Bioxytran's fundamental ratios provides investors with valuable insights into Bioxytran's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bioxytran is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Bioxytran operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about Bioxytran performance evaluation
Checking the ongoing alerts about Bioxytran for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Bioxytran help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bioxytran had very high historical volatility over the last 90 days | |
| Bioxytran has some characteristics of a very speculative penny stock | |
| Bioxytran has a very high chance of going through financial distress in the upcoming years | |
| Bioxytran currently holds 2.17 M in liabilities. Bioxytran has a current ratio of 0.09, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bioxytran until it has trouble settling it off, either with new capital or with free cash flow. So, Bioxytran's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bioxytran sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bioxytran to invest in growth at high rates of return. When we think about Bioxytran's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (4.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bioxytran currently holds about 500.68 K in cash with (839.44 K) of positive cash flow from operations. | |
| Roughly 66.0% of the company shares are held by company insiders |
- Analyzing Bioxytran's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioxytran's stock is overvalued or undervalued compared to its peers.
- Examining Bioxytran's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bioxytran's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioxytran's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Bioxytran's otc stock. These opinions can provide insight into Bioxytran's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bioxytran OTC Stock Analysis
When running Bioxytran's price analysis, check to measure Bioxytran's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioxytran is operating at the current time. Most of Bioxytran's value examination focuses on studying past and present price action to predict the probability of Bioxytran's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioxytran's price. Additionally, you may evaluate how the addition of Bioxytran to your portfolios can decrease your overall portfolio volatility.